Brief: SyndicateRoom Touts Ranking on CrowdRating

October 14, 2015 @ 8:20 am By JD Alois

Equity crowdfunding platform SyndicateRoom is touting its ranking on recenlty launched CrowdRating – a platform that rates offers and sites. As shared by SyndicateRoom, presently their deals come out on top, with both the highest average score and the highest rated investment opportunity, in current campaign Check4Cancer. Of course ratings of both platforms and investment deals will vary over time.

SyndicateRoom states it has an average score of 74.2%, ahead of other crowdfunding platforms, as of Sept 6th 2015. The system is said to provide objective information about available deals, working as a resource for both investors and entrepreneurs.

Check4Cancer has a top score of 96% in management and 93% in product. Check4Cancer offers the latest proven testing technologies and methodologies for early cancer detection.

Reg A - Form 1-A Filings Beta

Beta. Initial Form 1-A only. Target raise is the stated Amount to be Raised, totaled. Compared with the same dates one year earlier.

YTD: Jan 1, 2026 - Nov 4, 2026 vs Jan 1, 2025 - Nov 4, 2025

Number of Filings134Prior 129 +3.9%

Target Raise, Total$3.45BPrior $3.59B -3.8%

	This YTD	Year prior	Change
Filings	134	129	+3.9%
Target raise	$3.45B	$3.59B	-3.8%

Sponsored by the Crowded Media Group the leading digital news service covering the global Fintech Industry, including digital assets, crowdfunding, tokenization, and other innovations in capital markets. email us @CrowdfundInside

Source: DisclosureQuest. Initial Form 1-A only.

Created by Crowded Media Group

This display counts initial Form 1-A filings only. It does not represent subsequent filings, including Form 1-A/A amendments or Form 1-A POS post-qualification updates filed by the issuer. Amounts are the stated Amount to be Raised on the initial filing, not capital raised and not amounts revised in later filings.

0 0 votes

Article Rating

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments

Newest

Oldest Most Voted